Literature DB >> 12619955

Long-term management of asthma.

S K Kabra1, Rakesh Lodha.   

Abstract

Long-term management of asthma includes identification and avoidance of precipitating factors of asthma, pharmacotherapy and home management plan. Common precipitating factors include viral upper respiratory infections, exposure to smoke, dust, cold food and cold air. Avoidance of common precipitating factors has been shown to help in better control of asthma. Pharmacotherapy is the main stay of treatment of asthma. Commonly used drugs for better control of asthma are long and short acting bronchodilators, mast cell stabilizers, inhaled steroids, theophylline and steroid sparing agents. After assessment of severity most appropriate medications are selected. For mild episodic asthma the medications are short acting beta agonists as and when required. For mild persistent asthma: as and when required bronchodilators along with a daily maintenance treatment in form of low dose inhaled steroids or cromolyn or oral theophylline or leukotriene antagonists are required. Moderate persistent asthma should be treated with inhaled steroids along with long acting beta agonists for symptom control. For severe persistent asthma the recommended treatment includes inhaled steroids, long acting beta agonists with or without theophylline. If symptoms are not well controlled, a minimal dose of oral prednisolone preferably on alternate days may be needed in few patients. Patients should be followed up every 8-12 weeks. On each follow up visit patients should be examined by a doctor, compliance to medications should be checked and actual inhalation technique is observed. Depending on the assessment, medications may be decreased or stepped up. For exercise induced bronchoconstriction: cromolyn, short or long acting beta agonists or leukotriene antagonists may be used. In children with seasonal asthma, maintenance treatment according to assessed severity should be started 2 weeks in advance and continued throughout the season. These patients should be reassessed after discontinuing the treatment. Parents should be given a written plan for management of acute exacerbation at home.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619955     DOI: 10.1007/bf02722747

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  61 in total

1.  Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.

Authors:  B Knorr; J Matz; J A Bernstein; H Nguyen; B C Seidenberg; T F Reiss; A Becker
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

2.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.

Authors:  A A Verberne; C Frost; R J Roorda; H van der Laag; K F Kerrebijn
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

3.  Improvement of bronchial hyperresponsiveness in asthmatic children treated for concomitant sinusitis.

Authors:  C A Oliveira; D Solé; C K Naspitz; G S Rachelefsky
Journal:  Ann Allergy Asthma Immunol       Date:  1997-07       Impact factor: 6.347

4.  Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.

Authors:  J P Kemp; R J Dockhorn; G G Shapiro; H H Nguyen; T F Reiss; B C Seidenberg; B Knorr
Journal:  J Pediatr       Date:  1998-09       Impact factor: 4.406

5.  Factors associated with severe asthma.

Authors:  V H Ratageri; S K Kabra; S N Dwivedi; V Seth
Journal:  Indian Pediatr       Date:  2000-10       Impact factor: 1.411

6.  Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers.

Authors:  J H Wildhaber; S G Devadason; M J Hayden; E Eber; Q A Summers; P N LeSouëf
Journal:  Pediatr Pulmonol       Date:  1997-03

7.  Efficacy and safety of salmeterol in childhood asthma.

Authors:  W Lenney; S Pedersen; A L Boner; A Ebbutt; M M Jenkins
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

8.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

Authors:  L Agertoft; S Pedersen
Journal:  Respir Med       Date:  1994-05       Impact factor: 3.415

9.  A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.

Authors:  C T Furukawa; G G Shapiro; C W Bierman; M J Kraemer; D J Ward; W E Pierson
Journal:  Pediatrics       Date:  1984-10       Impact factor: 7.124

10.  Salmeterol xinafoate in children on high dose inhaled steroids.

Authors:  G Russell; D A Williams; P Weller; J F Price
Journal:  Ann Allergy Asthma Immunol       Date:  1995-11       Impact factor: 6.347

View more
  3 in total

Review 1.  Oral xanthines as maintenance treatment for asthma in children.

Authors:  P Seddon; A Bara; F M Ducharme; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 2.  Innate immunity and its regulation by mast cells.

Authors:  Ashley L St John; Soman N Abraham
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

3.  VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice.

Authors:  Jesse M Damsker; Blythe C Dillingham; Mary C Rose; Molly A Balsley; Christopher R Heier; Alan M Watson; Erik J Stemmy; Roslyn A Jurjus; Tony Huynh; Kathleen Tatem; Kitipong Uaesoontrachoon; Dana M Berry; Angela S Benton; Robert J Freishtat; Eric P Hoffman; John M McCall; Heather Gordish-Dressman; Stephanie L Constant; Erica K M Reeves; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.